Gama N1, Kumar K2,3, Ekengard E2, Haukka M4, Darkwa J5, Nordlander E6, Meyer D7,8.
Biometals. 2016 Jun;29(3):389-97. doi: 10.1007/s10534-016-9921-9. Epub 2016 Feb 27.HIV infection is known for replicating in proliferating CD(+) T-cells. Treatment of these cells with cytostatic (anti-proliferation) compounds such as hydroxyurea interferes with the cells's ability support HIV replication. Combinations of such cytostatic compounds with proven anti-retroviral drugs (like ddI) are known as virostatic, and have been shown to aid in the control of the infection. The use of two different drugs in virostatic combinations however, carries the risk of adverse effects including drug-drug interactions, which could lead to augmented toxicities and reduced efficacy. Read More